Patents by Inventor Paula A. Witt-Enderby

Paula A. Witt-Enderby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUTRACEUTICAL COMPOSITION AND DOSING REGIMEN
    Publication number: 20180193312
    Abstract: The present invention is a nutraceutical formulation, intended for oral administration, comprising co-administered if not co-formulated melatonin together with at least one of strontium, Vitamin D, and Vitamin K or their analogues. The nutraceutical combination or formulation is designed to be taken by mouth within about two hours prior to bedtime, and in fact should not be taken at any other time. The combination therapy gives new and unexpectedly improved results compared to the administration of melatonin alone.
    Type: Application
    Filed: July 25, 2017
    Publication date: July 12, 2018
    Applicant: ChronoSyn, LLC
    Inventors: Mark Herbert Swanson, Paula A Witt-Enderby
  • Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
    Patent number: 9370526
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: June 21, 2016
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis
  • Anti-cancer tamoxifen-melatonin hybrid ligand
    Patent number: 8785501
    Abstract: A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxytamoxifen and also melatonin, with the tamoxifen or 4-hydroxytamoxifen and melatonin's being linked by an unsubstituted C2-C6 alkyl linker between the tamoxifen amine and the carbonyl of melatonin.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: July 22, 2014
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis, David Lapinsky
  • Combination Hormone Replacement Therapy (HRT) and Melatonin to Prevent and Treat Mammary Cancer
    Publication number: 20140171396
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis
  • Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
    Patent number: 8618083
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: December 31, 2013
    Assignee: Duquesne University of the Holy Spirit
    Inventors: Paula A Witt-Enderby, Vicki L Davis
  • Bone implant
    Patent number: 8535706
    Abstract: A bone implant, and bone implant material, includes a calcium- and oxide-containing artificial graft material in a scaffold, to which melatonin and an optional cell adhesion peptide are absorbed or covalently linked.
    Type: Grant
    Filed: January 10, 2011
    Date of Patent: September 17, 2013
    Assignees: Duquesne University of the Holy Spirit
    Inventors: Paula A. Witt-Enderby, Kenneth McGowan, James Rutkowski, Ellen S. Gawalt, Rachelle Palchesko
  • Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand
    Publication number: 20130072539
    Abstract: A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxy-tamoxifen and also melatonin, with the tamoxifen or 5-hydroxy-tamoxifen and melatonin's being linked by an unsubstituted C2-C4 alkyl liner between the tamoxifen amine and the carbonyl of melatonin.
    Type: Application
    Filed: October 12, 2010
    Publication date: March 21, 2013
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis, David Lapinsky
  • ENHANCED BONE HEALING
    Publication number: 20130029960
    Abstract: The combined use—whether by adsorption or covalent linkage—of Melatonin adjacent any bone implant or graft, preferably any calcium- and oxide-containing artificial bone graft material, and more preferably a calcium aluminate composition. Alternatively, the bone graft or implant material may be used as a scaffold for tissue engineering.
    Type: Application
    Filed: January 10, 2011
    Publication date: January 31, 2013
    Inventors: Paula A. Witt-Enderby, Kenneth McGowan, James Rutkowski, Ellen S. Gawalt, Rachelle Palchesko
  • Combination Hormone Therapy for the Eye
    Publication number: 20110319370
    Abstract: An ophthalmic instillation composition which contains melatonin and at least one other hormone, typically an estrogen but also possibly testosterone or another aromatasable androgen. The instillation is designed to reduce or eliminate cataracts in men or women to which such an ophthalmic instillation composition is administered.
    Type: Application
    Filed: June 27, 2011
    Publication date: December 29, 2011
    Applicant: DUQUESNE UNIVERSITY OF THE
    Inventors: Moji Christianah Adeyeye, Paula A Witt-Enderby, Vicki L. Davis, Udaya K. Kotreka
  • Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
    Publication number: 20110028439
    Abstract: A combination hormone and melatonin therapy is provided to reduce the risk of developing, or to reduce the severity of, breast cancer by administering at least one estrogen hormone and optionally at least one progesterone-receptor-binding compound or composition and melatonin together, preferably at normal bed time.
    Type: Application
    Filed: July 20, 2010
    Publication date: February 3, 2011
    Inventors: Paula A. Witt-Enderby, Vicki L. Davis